A Berwyn-based biopharmaceutical company is entering an agreement to evaluate a candidate for treating rare pediatric epilepsy, writes John George for the Philadelphia Business Journal.

Virpax will work with the National Institute of Neurological Disorders and Stroke to identify “unmet medical needs” in epilepsy.  

The Epilepsy Therapy Screening Program will also focus on identifying products to address drugs that are resistant to epilepsy. Virpax’s NobrXiol product that treats epilepsy in children will be evaluated under the program.  

The biopharm company also develops non-addictive treatments for pain management, PTSD, and other disorders. The NobrXiol specifically is being developed to be delivered intranasally.  

Virpax is also going through a leadership transition Vinay Shah will be taking over from Christopher Chipman as Chief Financial Officer.  

Read more about the Berwyn-based biopharm company’s new research project in the Philadelphia Business Journal.  

Mayo Clinic explains “What is Epilepsy?”